electroCore (ECOR) Competitors

$5.99 -0.14 (-2.28%)

Closing price 04:00 PM Eastern

Extended Trading

$5.98 -0.01 (-0.17%)

As of 04:10 PM Eastern

ECOR vs. EMBC, LUCD, KRMD, CVRX, and PDEX

Should you buy electroCore stock or one of its competitors? MarketBeat compares electroCore with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with electroCore include Embecta (EMBC), Lucid Diagnostics (LUCD), KORU Medical Systems (KRMD), CVRx (CVRX), and Pro-Dex (PDEX). These companies are all part of the "medical equipment" industry.

How does electroCore compare to Embecta?

Embecta (NASDAQ:EMBC) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Embecta has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, electroCore has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Embecta has a net margin of 10.73% compared to electroCore's net margin of -44.08%. Embecta's return on equity of -23.96% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	10.73%	-23.96%	14.12%
electroCore	-44.08%	-1,956.38%	-83.30%

93.8% of Embecta shares are owned by institutional investors. Comparatively, 26.7% of electroCore shares are owned by institutional investors. 1.3% of Embecta shares are owned by insiders. Comparatively, 13.8% of electroCore shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Embecta currently has a consensus price target of $11.00, indicating a potential upside of 231.33%. electroCore has a consensus price target of $18.00, indicating a potential upside of 200.50%. Given Embecta's higher probable upside, equities analysts plainly believe Embecta is more favorable than electroCore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	3 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.40
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Embecta has higher revenue and earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.18	$95.40M	$1.90	1.75
electroCore	$32.03M	1.55	-$13.97M	-$1.77	N/A

In the previous week, Embecta had 6 more articles in the media than electroCore. MarketBeat recorded 8 mentions for Embecta and 2 mentions for electroCore. electroCore's average media sentiment score of 0.56 beat Embecta's score of 0.05 indicating that electroCore is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
electroCore	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Embecta beats electroCore on 11 of the 16 factors compared between the two stocks.

How does electroCore compare to Lucid Diagnostics?

electroCore (NASDAQ:ECOR) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

In the previous week, Lucid Diagnostics had 3 more articles in the media than electroCore. MarketBeat recorded 5 mentions for Lucid Diagnostics and 2 mentions for electroCore. electroCore's average media sentiment score of 0.56 beat Lucid Diagnostics' score of 0.25 indicating that electroCore is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
electroCore	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

26.7% of electroCore shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 13.8% of electroCore shares are held by company insiders. Comparatively, 6.8% of Lucid Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

electroCore presently has a consensus price target of $18.00, suggesting a potential upside of 200.50%. Lucid Diagnostics has a consensus price target of $4.13, suggesting a potential upside of 312.50%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Lucid Diagnostics is more favorable than electroCore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

electroCore has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

electroCore has a net margin of -44.08% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
electroCore	-44.08%	-1,956.38%	-83.30%
Lucid Diagnostics	-876.72%	N/A	-116.26%

electroCore has higher revenue and earnings than Lucid Diagnostics. electroCore is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
electroCore	$32.03M	1.55	-$13.97M	-$1.77	N/A
Lucid Diagnostics	$4.71M	43.11	-$58.01M	-$0.47	N/A

Summary

Lucid Diagnostics beats electroCore on 10 of the 16 factors compared between the two stocks.

How does electroCore compare to KORU Medical Systems?

KORU Medical Systems (NASDAQ:KRMD) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

58.6% of KORU Medical Systems shares are held by institutional investors. Comparatively, 26.7% of electroCore shares are held by institutional investors. 18.5% of KORU Medical Systems shares are held by company insiders. Comparatively, 13.8% of electroCore shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

KORU Medical Systems has a net margin of -5.27% compared to electroCore's net margin of -44.08%. KORU Medical Systems' return on equity of -13.61% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KORU Medical Systems	-5.27%	-13.61%	-8.33%
electroCore	-44.08%	-1,956.38%	-83.30%

KORU Medical Systems currently has a consensus target price of $7.25, indicating a potential upside of 75.12%. electroCore has a consensus target price of $18.00, indicating a potential upside of 200.50%. Given electroCore's higher probable upside, analysts clearly believe electroCore is more favorable than KORU Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KORU Medical Systems	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, KORU Medical Systems had 5 more articles in the media than electroCore. MarketBeat recorded 7 mentions for KORU Medical Systems and 2 mentions for electroCore. KORU Medical Systems' average media sentiment score of 0.97 beat electroCore's score of 0.56 indicating that KORU Medical Systems is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KORU Medical Systems	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
electroCore	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

KORU Medical Systems has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market. Comparatively, electroCore has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

KORU Medical Systems has higher revenue and earnings than electroCore. KORU Medical Systems is trading at a lower price-to-earnings ratio than electroCore, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KORU Medical Systems	$41.13M	4.62	-$2.64M	-$0.05	N/A
electroCore	$32.03M	1.55	-$13.97M	-$1.77	N/A

Summary

KORU Medical Systems beats electroCore on 13 of the 16 factors compared between the two stocks.

How does electroCore compare to CVRx?

electroCore (NASDAQ:ECOR) and CVRx (NASDAQ:CVRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

electroCore has a net margin of -44.08% compared to CVRx's net margin of -89.14%. CVRx's return on equity of -120.76% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
electroCore	-44.08%	-1,956.38%	-83.30%
CVRx	-89.14%	-120.76%	-48.38%

26.7% of electroCore shares are owned by institutional investors. Comparatively, 75.3% of CVRx shares are owned by institutional investors. 13.8% of electroCore shares are owned by company insiders. Comparatively, 13.9% of CVRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, CVRx had 1 more articles in the media than electroCore. MarketBeat recorded 3 mentions for CVRx and 2 mentions for electroCore. electroCore's average media sentiment score of 0.56 beat CVRx's score of 0.34 indicating that electroCore is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
electroCore	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
CVRx	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

electroCore presently has a consensus target price of $18.00, indicating a potential upside of 200.50%. CVRx has a consensus target price of $11.50, indicating a potential upside of 89.46%. Given electroCore's higher possible upside, analysts clearly believe electroCore is more favorable than CVRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CVRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.00

electroCore has higher earnings, but lower revenue than CVRx. electroCore is trading at a lower price-to-earnings ratio than CVRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
electroCore	$32.03M	1.55	-$13.97M	-$1.77	N/A
CVRx	$59.07M	2.73	-$53.31M	-$2.02	N/A

electroCore has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, CVRx has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Summary

CVRx beats electroCore on 11 of the 16 factors compared between the two stocks.

How does electroCore compare to Pro-Dex?

electroCore (NASDAQ:ECOR) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

electroCore has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Pro-Dex has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

26.7% of electroCore shares are held by institutional investors. Comparatively, 15.3% of Pro-Dex shares are held by institutional investors. 13.8% of electroCore shares are held by insiders. Comparatively, 45.9% of Pro-Dex shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Pro-Dex has a net margin of 16.08% compared to electroCore's net margin of -44.08%. Pro-Dex's return on equity of 22.78% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
electroCore	-44.08%	-1,956.38%	-83.30%
Pro-Dex	16.08%	22.78%	14.30%

In the previous week, electroCore and electroCore both had 2 articles in the media. Pro-Dex's average media sentiment score of 1.63 beat electroCore's score of 0.56 indicating that Pro-Dex is being referred to more favorably in the news media.

Company	Overall Sentiment
electroCore	Positive
Pro-Dex	Very Positive

electroCore currently has a consensus price target of $18.00, indicating a potential upside of 200.50%. Pro-Dex has a consensus price target of $70.00, indicating a potential upside of 11.80%. Given electroCore's higher possible upside, equities analysts clearly believe electroCore is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Pro-Dex has higher revenue and earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
electroCore	$32.03M	1.55	-$13.97M	-$1.77	N/A
Pro-Dex	$66.59M	3.00	$8.98M	$3.62	17.30

Summary

Pro-Dex beats electroCore on 11 of the 14 factors compared between the two stocks.

Get electroCore News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ECOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ECOR vs. The Competition

Export

Metric	electroCore	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$50.85M	$3.04B	$6.34B	$12.29B
Dividend Yield	N/A	1.96%	2.79%	5.32%
P/E Ratio	-3.38	12.40	17.81	22.73
Price / Sales	1.55	264.21	524.48	77.74
Price / Cash	N/A	57.57	44.13	56.13
Price / Book	-8.68	4.59	9.99	7.01
Net Income	-$13.97M	$74.99M	$3.55B	$335.05M
7 Day Performance	-6.84%	-2.36%	0.42%	-0.29%
1 Month Performance	-3.39%	-4.13%	-0.05%	1.15%
1 Year Performance	21.75%	36.31%	35.06%	34.79%

electroCore Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ECOR electroCore	2.6633 of 5 stars	$5.99 -2.3%	$18.00 +200.5%	+15.4%	$50.85M	$32.03M	N/A	50
EMBC Embecta	4.1489 of 5 stars	$3.41 +1.5%	$15.00 +339.9%	-75.1%	$199.34M	$1.08B	1.79	1,850	Analyst Forecast
LUCD Lucid Diagnostics	4.2588 of 5 stars	$1.04 +2.0%	$4.13 +296.6%	-23.1%	$199.16M	$4.71M	N/A	70	Earnings Report Insider Trade Gap Down
KRMD KORU Medical Systems	4.3986 of 5 stars	$4.00 -0.5%	$7.25 +81.3%	+35.6%	$184.65M	$41.13M	N/A	80	News Coverage
CVRX CVRx	2.3922 of 5 stars	$5.27 -23.8%	$11.50 +118.2%	-13.3%	$182.90M	$56.65M	N/A	160	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ECOR) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

electroCore (ECOR) Competitors